Physician profile
Brian Lynch
NPI 1831285147
$3,668.48
in general payments reported to CMS, 2019-2025
22 companies · $836 in 2025
The $836 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $162 · 2021: $316 · 2022: $531 · 2023: $624 · 2024: $742 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $655.19 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $630.77 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $532.99 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Coopervision INC. | $316.98 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $309.42 | 2019-2025 | |
| Allergan, INC. | $204.88 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $168.40 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $156.88 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Glaukos Corporation | $110.30 | 2025 | Photrexa Viscous and Photrexa |
| Dompe US, INC. | $101.70 | 2024-2025 | Oxervate |
| Abbvie INC. | $53.85 | 2022-2024 | |
| Oyster Point Pharma, INC. | $45.70 | 2023-2025 | Tyrvaya |
| Rxsight INC | $45.45 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $38.60 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $37.22 | 2019 | |
| Aerie Pharmaceuticals, INC. | $35.56 | 2021 | |
| Eyevance Pharmaceuticals LLC | $24.94 | 2021-2022 | |
| Sight Sciences, INC. | $23.23 | 2022 | |
| Thea Pharma INC. | $20.53 | 2023 | Iyuzeh |
| Abb Con-Cise Optical Group LLC | $16.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.